MGUS and SMM
| Diagnosis . | Disease definition . | Progression rate . | Reference . |
|---|---|---|---|
| Non-IgM MGUS | Both criteria must be met: | 1% per year | 7 |
| Serum M protein (IgG or IgA) <3 g/dL and clonal BMPCs <10%, and | |||
| Absence of myeloma defining events or amyloidosis | |||
| SMM* | Both criteria must be met: | 10% per year in first 5 y. Light-chain SMM has a lower progression rate of 5% per year | 7,15 |
| Serum M protein (IgG or IgA) ≥3 g/dL or urinary M protein ≥500 mg/24 h and/or clonal BMPCs 10%-60%, and | |||
| Absence of MDEs or amyloidosis |
| Diagnosis . | Disease definition . | Progression rate . | Reference . |
|---|---|---|---|
| Non-IgM MGUS | Both criteria must be met: | 1% per year | 7 |
| Serum M protein (IgG or IgA) <3 g/dL and clonal BMPCs <10%, and | |||
| Absence of myeloma defining events or amyloidosis | |||
| SMM* | Both criteria must be met: | 10% per year in first 5 y. Light-chain SMM has a lower progression rate of 5% per year | 7,15 |
| Serum M protein (IgG or IgA) ≥3 g/dL or urinary M protein ≥500 mg/24 h and/or clonal BMPCs 10%-60%, and | |||
| Absence of MDEs or amyloidosis |
Excludes patients without end-organ damage who meet the revised definition of MM; namely, clonal BMPCs ≥60% or serum FLC ratio ≥100 (plus measurable involved FLC level ≥100 mg/L), or >1 focal lesion on MRI scan.